Tweet
ANSV - here's a new one to look at:
ANSV just got FDA approval last week, and the stock is movin' on up!
Anesiva Shares Rise on FDA Drug Approval
Friday August 17, 2:03 pm ET
Anesiva Shares Jump As FDA Approves Zingo, Analysts Issue Positive Outlook NEW YORK (AP) -- Shares of biotechnology company Anesiva Inc. jumped Friday after the Food and Drug Adminstration approved its pain drug Zingo earlier than expected.Shares of the San Francisco-based company rose jumped 43 cents, or 8.2 percent, to $5.62 in afternoon trading on sharply higher volume. In the past year, the stock has ranged between $4.92 and $8.71.
In a note to investors, Pacific Growth Equities analyst Liana Moussatos reiterated a "Buy" rating on Anesiva, calling it an attractive investment as she anticipates a significant increase in the company's valuation.Zingo is a needle-free system that contains sterile lidocaine powder designed to give fast relief for pain associated with venous access procedures, such as the drawing of blood. The product is indicated for children between 3 and 18 years old.
Anesiva said the FDA issued its approval five weeks ahead of the PDUFA, the date the agency had agreed to make a decision on the application.
Along with today's approval of the drug for pediatric use, Moussatos is optimistic about the product's potential approval for use in adults. Moussatos estimates Anesiva could reach profitability in 2011 with about $172 million in full-year Zingo sales, and also pointed to possible revenue opportunities from potential Zingo commercial partnerships and licensing agreements.
The company has another drug, Adlea, in mid-stage clinical trials that Moussatos thinks will receive approval for treatment of post-surgical pain in 2009.
"With multiple product candidates in various stages of development, we believe Anesiva has diversified pipeline risk, an attractive valuation, and a solid investment opportunity," Moussatos said.
Slightly less optimistic, Lehman Brothers analyst Ajim Tamboli reiterated an "Equal Weight" rating on the stock, expressing wariness on the outlook for Zingo and Adlea.
In a note to clients, Tamboli said questions surround the commercial potential for Zingo due to a fragmented topical anesthetic market. For Adlea, he said low-cost alternatives such as corticosteroid injection could affect the drug's popularity.
Still, the analyst noted the drugs' low risk based on clinical data.
Anesiva Shares Rise on FDA Drug Approval
Friday August 17, 2:03 pm ET
Anesiva Shares Jump As FDA Approves Zingo, Analysts Issue Positive Outlook NEW YORK (AP) -- Shares of biotechnology company Anesiva Inc. jumped Friday after the Food and Drug Adminstration approved its pain drug Zingo earlier than expected.Shares of the San Francisco-based company rose jumped 43 cents, or 8.2 percent, to $5.62 in afternoon trading on sharply higher volume. In the past year, the stock has ranged between $4.92 and $8.71.
In a note to investors, Pacific Growth Equities analyst Liana Moussatos reiterated a "Buy" rating on Anesiva, calling it an attractive investment as she anticipates a significant increase in the company's valuation.Zingo is a needle-free system that contains sterile lidocaine powder designed to give fast relief for pain associated with venous access procedures, such as the drawing of blood. The product is indicated for children between 3 and 18 years old.
Anesiva said the FDA issued its approval five weeks ahead of the PDUFA, the date the agency had agreed to make a decision on the application.
Along with today's approval of the drug for pediatric use, Moussatos is optimistic about the product's potential approval for use in adults. Moussatos estimates Anesiva could reach profitability in 2011 with about $172 million in full-year Zingo sales, and also pointed to possible revenue opportunities from potential Zingo commercial partnerships and licensing agreements.
The company has another drug, Adlea, in mid-stage clinical trials that Moussatos thinks will receive approval for treatment of post-surgical pain in 2009.
"With multiple product candidates in various stages of development, we believe Anesiva has diversified pipeline risk, an attractive valuation, and a solid investment opportunity," Moussatos said.
Slightly less optimistic, Lehman Brothers analyst Ajim Tamboli reiterated an "Equal Weight" rating on the stock, expressing wariness on the outlook for Zingo and Adlea.
In a note to clients, Tamboli said questions surround the commercial potential for Zingo due to a fragmented topical anesthetic market. For Adlea, he said low-cost alternatives such as corticosteroid injection could affect the drug's popularity.
Still, the analyst noted the drugs' low risk based on clinical data.
Comment